Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 22, Issue 3, 2007, Pages 309-318

  Giovannoni, Maria P ^a   Cesari, Nicoletta ^a   Graziano, Alessia ^a   Vergelli, Claudia ^a   Biancalani, Claudio ^a   Biagini, Pierfrancesco ^a   Piaz, Vittorio Dal ^a  

^a Dipartimento di Scienze Farmaceutiche   (Italy)

Author keywords

Inhibitors; PDE4 subtypes; Pyrrolopyridazinones; Selectivity; TNF

Indexed keywords

3 ETHYL 4 NITRO 6 PHENYL 5 PROPIONYLPYRIDAZIN 3(2H) ONE; 3 ETHYL 4 PHENYLISOXAZOLO[3,4 D]PYRIDAZINE 7(6H) ONE; 3,6 DIETHYL 4 PHENYLISOXAZOLO[3,4 D]PYRIDAZIN 7(6H) ONE; 4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 4 PHENYL 3 N PROPYLISOXAZOLO[3,4 D]PYRIDAZINE 7(6H) ONE; 5 ACETYL 6 (3 CHLOROPHENYL) 2 ETHYL 4 NITROPYRIDAZIN 3(2H) ONE; 5 BUTYRYL 2 ETHYL 6 PHENYL 4 NITROPYRIDAZIN 3(2H) ONE; 6 ETHYL 4 PHENYL 3 N PROPYLISOXAZOLO[3,4 D]PYRIDAZIN 7(6H) ONE; CARBOXYLIC ACID DERIVATIVE; CILOMILAST; ETHYL 1 BENZYL 6,7 DIHYDRO 6 ETHYL 3 METHYL 7 OXO 4 PHENYL 1H PYRROLO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; ETHYL 1,6 DIETHYL 6,7 DIHYDRO 3 METHYL 7 OXO 4 PHENYL 1H PYRROLO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; ETHYL 3,6 DIETHYL 6,7 DIHYDRO 4 PHENYL 7 OXO 1H PYRROLO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; ETHYL 4 (3 CHLOROPHENYL) 6,7 DIHYDRO 6 ETHYL 3 METHYL 7 OXO 1H PYRROLO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; ETHYL 4 BENZOYL 5 PROPYLISOXAZOLE 3 CARBOXYLATE; ETHYL 6,7 DIHYDRO 1,3 DIMETHYL 6 ETHYL 7 OXO 4 PHENYL 1H PYRROLO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; ETHYL 6,7 DIHYDRO 3 METHYL 7 OXO4 PHENYL 6 N PROPYL 1H PYRROLO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; ETHYL 6,7 DIHYDRO 6 ETHYL 1 ISOPROPYL 3 METHYL 7 OXO 4 PHENYL 1H PYRROLO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; ETHYL 6,7 DIHYDRO 6 ETHYL 3 METHYL 7 OXO 4 PHENYL 1 PROPYL 1H PYRROLO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; ETHYL 6,7 DIHYDRO 6 ETHYL 4 PHENYL 3 N PROPYL 7 OXO 1H PYRROLO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PYRIDAZINE DERIVATIVE; PYRIDAZINONE DERIVATIVE; PYRROLO[2,3 D]PYRIDAZINONE; ROFLUMILAST; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CATALYTIC DOMAIN; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; PYRROLES; ROLIPRAM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34547733625     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360601114700     Document Type: Article

References (40)

1. Torphy, TJ (1998) Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med, 157, pp. 351-370.
2. Houslay, MD (2001) PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol, 69, pp. 249-315.
3. Piaz, V Dal and Giovannomi, MP (2000) Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur J Med Chem, 35, pp. 463-480.
4. Bousquet, J., Chanez, P., Vignola, AM, Lacoste, JY and Michel, FB (1994) Eosinophil inflammation in asthma. Am J Respir Crit Care Med, 150, pp. S33-S38.
5. Whelan, CJ (1996) Inhibition of PAF-, LPS-, and cytokine-induced granulocyte accumulation in guinea pig lung by dexamethasone: Evidence that inhibition of IL-5 release is responsible for the selective inhibition of eosinophilia by glucocorticoids in guinea-pigs. Inflamm Res, 45:4, pp. 166-170.
6. Nyman, U., Mussener, A., Larsson, E., Lorentzen, J. and Klareskog, L. (1997) Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor. Rolipram Clin Exp Immunol, 108, pp. 415-419.
7. Spina, D. (2003) Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs, 63, pp. 2575-2594.
8. Hanifin, JM, Chan, SC, Cheng, JB, Tofte, SJ, Henderson, WRJr, Kirby, DS and Weiner, ES (1996) Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol, 107, pp. 51-56.
9. Muller, T., Engels, P. and Fozard, JR (1996) Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition. TIPS, 17, pp. 294-298.
10. Schneider, HH, Schmiechen, R., Brezinski, M. and Seidler, J. (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol, 127, pp. 105-115.
11. Souness, JE and Rao, S. (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal, 9, pp. 227-236.
12. Kaulen, P., Bruning, G., Schneider, HH, Sarter, N. and Baumgarten, HG (1989) Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res, 503, pp. 229-245.
13. Buckle, DR, Arch, JR, Connolly, BJ, Fenwick, AE, Foster, KA, Murray, KJ, Readshaw, SA, Smallridge, M. and Smith, DG (1994) Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine. J Med Chem, 37:4, pp. 476-485.
14. Larson, LJ, Pino, MV, Geiger, LE and Simeone, CR (1996) The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol, 78, pp. 44-49.
15. Burnouf, C. and Pruniax, MP (2002) Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des, 8, pp. 1255-1296.
16. Christensen, SB, Guider, AM, Forster, CJ, Gleason, JG, Bender, PE, Karpinski, JM, DeWolf, WE, Barnette, MS, Underwood, DC, Griswold, DE, Cielinski, LB, Burman, M., Bochnowicz, S., Osborn, RR, Manning, CD, Grous, M., Hillegas, LM, Bartus, JO, Ryan, MD, Eggleston, DS, Haltiwanger, RC and Torphy, TJ (1998) 1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J Med Chem, 41, pp. 821-835.
17. Barnette, MS, Christensen, SB, Essayan, DM, Grous, M., Prabhakar, U., Rush, JA, Kagey-Sobotka, A. and Torphy, TJ (1998) SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions. J Pharmacol Exp Ther, 284, pp. 420-426.
18. Karish, SB and Gagnon, JM (2006) The potential role of roflumilast: The new phosphodiesterase-4 inhibitor. Ann Pharmacother, 40:6, pp. 1096-1104.
19. Hatzeman, A. and Schudt, C. (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther, 297, pp. 267-279.
20. Perry, MJ, O'Connell, J., Walker, C., Crabbe, T., Baldock, D., Russell, A., Lumb, S., Huang, Z., Howat, D., Alle, R., Merriman, M., Walls, J., Daniel, T., Hughes, B., Laliberte, F., Higgs, GA and Owens, RJ (1998) CDP840: A novel inhibitor of PDE-4. Cell Biochem Biophys, 29, pp. 113-132.
21. Aoki, M., Fukunaga, M., Sugimoto, T., Hirano, Y., Kobayashi, M., Honda, K. and Yamada, T. (2001) Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther, 298, pp. 1142-1149.
22. Compton, CH, Gubb, J., Nieman, RB, Edelson, J., Amit, O., Bakst, A., Ayres, JG, Creemers, JPHH, Schultze-Werninghaus, G., Brambilla, C. and Barnes, NC (2001) Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study. Lancet, 358, pp. 265-270.
23. Bateman, ED, Izquierdio, JL, Harnest, U., Hofbauer, P., Magvar, P., Schmid-Wirlitsch, C., Leichtl, S. and Bredenbroker, D. (2006) Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol, 96, pp. 679-686.
24. Lipworth, BJ (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, 365, pp. 167-175.
25. Harbinson, PL, MacLeod, D., Hawksworth, R., O'Toole, S., Sullivan, PJ, Kilfeather, S., Page, CP, Costello, J., Holgate, ST and Lee, TH (1997) The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J, 10, pp. 1008-1014.
26. Alexander, RP, Warrellow, GJ, Eaton, MAW, Boyd, EC, Head, JC, Porter, JR, Brown, JA, Reuberson, JT, Hutchinson, B., Turner, P., Boyce, B., Barnes, D., Mason, B., Cannell, A., Taylor, JR, Zomaya, A., Millican, A., Leonard, J., Morphy, R., Wales, M., Allen, RA, Gozzard, N. and Hughes, B. (2002) CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors. Bioorg Med Chem Lett, 12, pp. 1451-1456.
27. Aoki, M., Kobayashi, M., Ishikawa, J., Saita, Y., Terai, Y., Takayama, K., Miyata, K. and Yamada, T. (2000) A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. J Pharmacol Exp Ther, 295, pp. 255-260.
28. Hersperger, R., Bray-French, K., Mazzoni, L. and Muller, T. (2000) Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: A novel class of potent and selective phosphodiesterase type 4D inhibitors. J Med Chem, 43, pp. 675-682.
29. Robichaud, A., Stamatiou, PB, Jin, SLC, Lachance, N., MacDonald, D., Lalibertè, F., Liu, S., Huang, Z., Conti, M. and Chan, CC (2002) Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest, 110, pp. 1045-1052.
30. Piaz, V Dal, Ciciani, G. and Turco, G. (1989) Oxidative cleavage of 7-oxo-6,7-dihydroisoxazolo[3,4-d]pyridazines by cerium(IV) ammonium nitrate. A synthetic approach to new 5-acyl-4-nitro-3-oxo-2,3-dihydropyridazines. Synthesis, 3, pp. 213-214.
31. Piaz, V Dal, Ciciani, G. and Giovannoni, MP (1997) Synthesis of 4,5-functionalized-2-methyl-6-(substituted aryl)-3 (2H)-pyridazinones: A new group of potent platelet aggregation inhibitors. Il Farmaco, 52, pp. 173-178.
32. Renzi, G., Piaz, V Dal and Musante, C. (1968) Condensation between b-oxobenzoyl compounds and hydroximic chloride. Gazz Chim Ital, 98, pp. 656-666.
33. Renzi, G. and Pinzauti, S. (1969) New derivatives of isoxazolo[3,4-d]pyridazin-7(6H)-one. Il Farmaco Ed Sci, 24, pp. 885-889.
34. Piaz, V Dal, Ciciani, G., Giovannoni, MP and Franconi, F. (1996) Synthesis and evaluation as platelet aggregation inhibitors of 6-phenyl-2,4-substituted-3(2H)-pyridazinones and their rigid analogues benzo[h]cinnolin-3,5-diones. Drug Des Disc, 14, pp. 53-75.
35. Adams, J. and Hauser, CR (1945) Condensations. XXIX. Acylation of ketones with aliphatic anhydrides by means of BF3. Synthesis of β-diketones. J Am Chem Soc, 67, pp. 284-286.
36. Gristwood, RW, Beleta, J., Bou, J., Cardelus, I., Fernandez, AG, Lenas, J. and Berga, P. (1992) Studies on the cardiac actions of flosequinam in vitro. Br J Pharmacol, 105, pp. 985-991.
37. Thompson, WJ and Strada, SJ (1984) Method of Enzymatic Analysis, pp. 127-134. Verlag-Chemie, Weinheim
38. Percival, MD, Yeh, B. and Falgueyret, JP (1997) Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A). Biochem. Biophys Res Commun, 241, pp. 175-180.
39. Schneider, HH, Schmiechen, R., Brezinski, M. and Seidler, J. (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol, 127, pp. 105-115.
40. Gantner, F., Kupferschmitd, R., Schudt, C., Wendel, A. and Hatzelmann, A. (1997) In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol, 121, pp. 221-231.